BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Figueras-Aloy J, Manzoni P, Paes B, Simões EA, Bont L, Checchia PA, Fauroux B, Carbonell-Estrany X. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease. Infect Dis Ther 2016;5:417-52. [PMID: 27628014 DOI: 10.1007/s40121-016-0130-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis 2017;17:687. [PMID: 29041909 DOI: 10.1186/s12879-017-2803-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
2 Aikphaibul P, Theerawit T, Sophonphan J, Wacharachaisurapol N, Jitrungruengnij N, Puthanakit T. Risk factors of severe hospitalized respiratory syncytial virus infection in tertiary care center in Thailand. Influenza Other Respir Viruses 2021;15:64-71. [PMID: 32783380 DOI: 10.1111/irv.12793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Lanari M, Anderson EJ, Sheridan-Pereira M, Carbonell-Estrany X, Paes B, Rodgers-Gray BS, Fullarton JR, Grubb E, Blanken M. Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies. Epidemiol Infect 2020;148:e170. [PMID: 32799945 DOI: 10.1017/S0950268820001661] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Masarweh K, Gur M, Leiba R, Bar-yoseph R, Toukan Y, Nir V, Gut G, Ben-david Y, Hakim F, Bentur L. Factors predicting length of stay in bronchiolitis. Respiratory Medicine 2020;161:105824. [DOI: 10.1016/j.rmed.2019.105824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Cetinkaya M, Oral TK, Karatekin S, Cebeci B, Babayigit A, Yesil Y. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis. Eur J Clin Microbiol Infect Dis 2017;36:1629-34. [PMID: 28391538 DOI: 10.1007/s10096-017-2976-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Trevisan M, Di Antonio V, Radeghieri A, Palù G, Ghildyal R, Alvisi G. Molecular Requirements for Self-Interaction of the Respiratory Syncytial Virus Matrix Protein in Living Mammalian Cells. Viruses 2018;10:E109. [PMID: 29510513 DOI: 10.3390/v10030109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Narayan O, Bentley A, Mowbray K, Hermansson M, Pivonka D, Kemadjou EN, Belsey J. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. J Med Econ 2020;23:1640-52. [PMID: 33107769 DOI: 10.1080/13696998.2020.1836923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 German P, Xin Y, Chien JW, Weng W, Mackman R, Lewis SA, Meng A, Ling J, Mathias A. Phase 1 First-in-Human, Single- and Multiple-Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection. J Clin Pharmacol 2018;58:1025-34. [PMID: 29663420 DOI: 10.1002/jcph.1112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
9 Fauroux B, Simões EAF, Checchia PA, Paes B, Figueras-Aloy J, Manzoni P, Bont L, Carbonell-Estrany X. The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood. Infect Dis Ther 2017;6:173-97. [PMID: 28357706 DOI: 10.1007/s40121-017-0151-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 13.0] [Reference Citation Analysis]
10 Chatterjee A, Mavunda K, Krilov LR. Current State of Respiratory Syncytial Virus Disease and Management. Infect Dis Ther 2021;10:5-16. [PMID: 33660239 DOI: 10.1007/s40121-020-00387-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mosalli R, Alqarni SA, Khayyat WW, Alsaidi ST, Almatrafi AS, Bawakid AS, Paes B. Respiratory syncytial virus nosocomial outbreak in neonatal intensive care: A review of the incidence, management, and outcomes. Am J Infect Control 2021:S0196-6553(21)00711-2. [PMID: 34736992 DOI: 10.1016/j.ajic.2021.10.027] [Reference Citation Analysis]
12 Steiner L, Diesner SC, Voitl P. Risk of infection in the first year of life in preterm children: An Austrian observational study. PLoS One 2019;14:e0224766. [PMID: 31816626 DOI: 10.1371/journal.pone.0224766] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
13 Manzoni P, Figueras-Aloy J, Simões EAF, Checchia PA, Fauroux B, Bont L, Paes B, Carbonell-Estrany X. Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases. Infect Dis Ther 2017;6:383-411. [PMID: 28653300 DOI: 10.1007/s40121-017-0160-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
14 Mitchell I, Wong SK, Paes B, Ruff M, Bjornson C, Li A, Lanctôt KL; CARESS investigators. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016). Eur J Clin Microbiol Infect Dis 2018;37:1345-52. [PMID: 29728782 DOI: 10.1007/s10096-018-3256-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Paes B, Fullarton JR, Rodgers-Gray BS, Carbonell-Estrany X. Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants. Curr Med Res Opin 2021;37:1149-53. [PMID: 33813989 DOI: 10.1080/03007995.2021.1911974] [Reference Citation Analysis]
16 Townsi N, Laing IA, Hall GL, Simpson SJ. The impact of respiratory viruses on lung health after preterm birth. Eur Clin Respir J 2018;5:1487214. [PMID: 30128088 DOI: 10.1080/20018525.2018.1487214] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
17 Blanken MO, Paes B, Anderson EJ, Lanari M, Sheridan-Pereira M, Buchan S, Fullarton JR, Grubb E, Notario G, Rodgers-Gray BS, Carbonell-Estrany X. Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. Pediatr Pulmonol 2018;53:605-12. [PMID: 29405612 DOI: 10.1002/ppul.23960] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
18 Pierangeli A, Statzu M, Nenna R, Santinelli L, Petrarca L, Frassanito A, Gentile M, Antonelli G, Midulla F, Scagnolari C. Interferon lambda receptor 1 (IFNL1R) transcript is highly expressed in rhinovirus bronchiolitis and correlates with disease severity. J Clin Virol 2018;102:101-9. [PMID: 29549834 DOI: 10.1016/j.jcv.2018.03.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
19 Kenmoe S, Kengne-Nde C, Modiyinji AF, La Rosa G, Njouom R. Comparison of health care resource utilization among preterm and term infants hospitalized with Human Respiratory Syncytial Virus infections: A systematic review and meta-analysis of retrospective cohort studies. PLoS One 2020;15:e0229357. [PMID: 32084214 DOI: 10.1371/journal.pone.0229357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Stray K, Perron M, Porter DP, Anderson F, Lewis SA, Perry J, Miller M, Cihlar T, DeVincenzo J, Chien JW, Jordan R. Drug Resistance Assessment Following Administration of Respiratory Syncytial Virus (RSV) Fusion Inhibitor Presatovir to Participants Experimentally Infected With RSV. J Infect Dis 2020;222:1468-77. [PMID: 31971597 DOI: 10.1093/infdis/jiaa028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
21 Grut V, Söderström L, Naumburg E. National cohort study showed that infants with Down's syndrome faced a high risk of hospitalisation for the respiratory syncytial virus. Acta Paediatr 2017;106:1519-24. [DOI: 10.1111/apa.13937] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
22 Sawada A, Ito T, Yamaji Y, Nakayama T. Chimeric Measles Virus (MV/RSV), Having Ectodomains of Respiratory Syncytial Virus (RSV) F and G Proteins Instead of Measles Envelope Proteins, Induced Protective Antibodies against RSV. Vaccines (Basel) 2021;9:156. [PMID: 33669275 DOI: 10.3390/vaccines9020156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Civra A, Francese R, Donalisio M, Tonetto P, Coscia A, Sottemano S, Balestrini R, Faccio A, Cavallarin L, Moro GE, Bertino E, Lembo D. Human Colostrum and Derived Extracellular Vesicles Prevent Infection by Human Rotavirus and Respiratory Syncytial Virus in Vitro. J Hum Lact 2021;37:122-34. [PMID: 33534629 DOI: 10.1177/0890334420988239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Charlton CL, Babady E, Ginocchio CC, Hatchette TF, Jerris RC, Li Y, Loeffelholz M, McCarter YS, Miller MB, Novak-Weekley S, Schuetz AN, Tang YW, Widen R, Drews SJ. Practical Guidance for Clinical Microbiology Laboratories: Viruses Causing Acute Respiratory Tract Infections. Clin Microbiol Rev 2019;32:e00042-18. [PMID: 30541871 DOI: 10.1128/CMR.00042-18] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
25 Simões EAF, Bont L, Manzoni P, Fauroux B, Paes B, Figueras-Aloy J, Checchia PA, Carbonell-Estrany X. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther 2018;7:87-120. [PMID: 29470837 DOI: 10.1007/s40121-018-0188-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 14.0] [Reference Citation Analysis]
26 Wang DY, Saleem M, Paes BA, Mitchell I, Li A, Lanctôt KL. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab. Pediatric Infectious Disease Journal 2019;38:775-80. [DOI: 10.1097/inf.0000000000002297] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Thwaites R, Buchan S, Fullarton J, Morris C, Grubb E, Rodgers-Gray B, Coutts J. Clinical burden of severe respiratory syncytial virus infection during the first 2 years of life in children born between 2000 and 2011 in Scotland. Eur J Pediatr 2020;179:791-9. [PMID: 31912234 DOI: 10.1007/s00431-019-03564-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Kong AM, Winer IH, Zimmerman NM, Diakun D, Bloomfield A, Gonzales T, Fergie J, Goldstein M, Krilov LR. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data. Am J Perinatol 2021. [PMID: 34704241 DOI: 10.1055/s-0041-1736581] [Reference Citation Analysis]
29 Bjornson C, Chan P, Li A, Paes B, Lanctôt KL, Mitchell I. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need? Eur J Clin Microbiol Infect Dis 2018;37:1113-8. [PMID: 29557081 DOI: 10.1007/s10096-018-3225-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
30 Mitra S, El Azrak M, Mccord H, Paes BA. Hospitalization for Respiratory Syncytial Virus in Children with Down Syndrome Less than 2 Years of Age: A Systematic Review and Meta-Analysis. The Journal of Pediatrics 2018;203:92-100.e3. [DOI: 10.1016/j.jpeds.2018.08.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
31 Checchia PA, Paes B, Bont L, Manzoni P, Simões EA, Fauroux B, Figueras-Aloy J, Carbonell-Estrany X. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease. Infect Dis Ther 2017;6:37-56. [PMID: 28070870 DOI: 10.1007/s40121-016-0142-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
32 Carbonell-Estrany X, Rodgers-Gray BS, Paes B. Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries. Expert Rev Anti Infect Ther 2021;19:419-41. [PMID: 32972198 DOI: 10.1080/14787210.2021.1828866] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Goldstein M, Fergie J, Krilov LR. Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States. Infect Dis Ther 2021;10:17-26. [PMID: 33656649 DOI: 10.1007/s40121-020-00388-1] [Reference Citation Analysis]
34 Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, Chawla R, Dotta A, Rodríguez Fernández R, Resch B, Carbonell-Estrany X. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev 2020;33:35-44. [PMID: 31060948 DOI: 10.1016/j.prrv.2018.12.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
35 Amand C, Tong S, Kieffer A, Kyaw MH. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis. BMC Health Serv Res 2018;18:294. [PMID: 29678177 DOI: 10.1186/s12913-018-3066-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
36 Wingert A, Pillay J, Moore DL, Guitard S, Vandermeer B, Dyson MP, Sinilaite A, Tunis M, Hartling L. Burden of illness in infants and young children hospitalized for respiratory syncytial virus: A rapid review. Can Commun Dis Rep 2021;47:381-96. [PMID: 34650335 DOI: 10.14745/ccdr.v47i09a05] [Reference Citation Analysis]
37 Satav A, Crow R, Potdar V, Dani V, Satav S, Chadha M, Hessong D, Carosone-Link P, Palaskar S, Simões EAF. The Burden of Respiratory Syncytial Virus in Children Under 2 Years of Age in a Rural Community in Maharashtra, India. Clin Infect Dis 2021;73:S238-47. [PMID: 34472575 DOI: 10.1093/cid/ciab508] [Reference Citation Analysis]
38 Al Shibli A, Nouredin MB, Al Amri A, Iram D, Narchi H. Epidemiology of Bronchiolitis in Hospitalized Infants at Tawam Hospital, Al Ain, United Arab Emirates. Open Respir Med J 2021;15:7-13. [PMID: 34249176 DOI: 10.2174/1874306402115010007] [Reference Citation Analysis]
39 Fauroux B, Hascoët JM, Jarreau PH, Magny JF, Rozé JC, Saliba E, Schwarzinger M. Risk factors for bronchiolitis hospitalization in infants: A French nationwide retrospective cohort study over four consecutive seasons (2009-2013). PLoS One 2020;15:e0229766. [PMID: 32142528 DOI: 10.1371/journal.pone.0229766] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Silva DGBPD, Almeida FJ, Arnoni MV, Sáfadi MAP, Mimica MJ, Jarovsky D, Rossetti GPDA, Magalhães M, Oliveira DBLD, Thomazelli LM, Colmanetti TC, Durigon EL, Berezin EN. First report of two consecutive respiratory syncytial virus outbreaks by the novel genotypes ON‐1 and NA‐2 in a neonatal intensive care unit. Jornal de Pediatria (Versão em Português) 2020;96:233-9. [DOI: 10.1016/j.jpedp.2018.10.008] [Reference Citation Analysis]
41 Muganthan T, Boyle EM. Early childhood health and morbidity, including respiratory function in late preterm and early term births. Semin Fetal Neonatal Med 2019;24:48-53. [PMID: 30348617 DOI: 10.1016/j.siny.2018.10.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
42 Paes B, Li A, Kim D, Lanctot KL, Mitchell I; CARESS Investigators. A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab. Am J Perinatol 2021;38:e129-36. [PMID: 32232817 DOI: 10.1055/s-0040-1708804] [Reference Citation Analysis]